TrialCurveConvalescent plasma for severe COVID-19 in cancer patients: reconstructed Kaplan–Meier curves
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Nat Cancer. 2022 Dec 29;4(1):96–107. doi: 10.1038/s43018-022-00503-w |
|---|---|
| DOI | 10.1038/s43018-022-00503-w |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Overall survival (secondary endpoint) — Overall study cohort (groups 1–4)
From figure panel a · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Plasma therapy not reached; Standard of care not reached. Survival at 24 days: Plasma therapy 88%; Standard of care 86%. Hazard ratio Plasma therapy vs Standard of care 0.73 (95% CI 0.34–1.56).
| Arm | N | Events | Median (Days) |
|---|---|---|---|
| Plasma therapy | 68 | 12 | not reached |
| Standard of care | 66 | 15 | not reached |
- Plasma therapy vs Standard of care: reconstructed HR 0.73 (95% CI 0.34–1.56)
Landmark survival (reconstructed)
| Time | Plasma therapy | Standard of care |
|---|---|---|
| 24 d | 87.9% | 85.7% |
| 48 d | 83.2% | 77.1% |
| 72 d | 81.5% | 75.3% |
Overall survival (secondary endpoint) — Group 1
From figure panel c · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Plasma therapy not reached; Standard of care not reached. Survival at 24 days: Plasma therapy 93%; Standard of care 69%. Hazard ratio Plasma therapy vs Standard of care 0.26 (95% CI 0.07–0.97).
| Arm | N | Events | Median (Days) |
|---|---|---|---|
| Plasma therapy | 28 | 3 | not reached |
| Standard of care | 28 | 9 | not reached |
- Plasma therapy vs Standard of care: reconstructed HR 0.26 (95% CI 0.07–0.97)
Landmark survival (reconstructed)
| Time | Plasma therapy | Standard of care |
|---|---|---|
| 24 d | 92.9% | 69.1% |
| 48 d | 89.3% | 69.1% |
| 72 d | 89.3% | 64.8% |
Overall survival (secondary endpoint) — Combined groups 2–4
From figure panel d · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Standard of care not reached; Plasma therapy not reached. Survival at 24 days: Standard of care 95%; Plasma therapy 84%. Hazard ratio Standard of care vs Plasma therapy 0.74 (95% CI 0.28–1.99).
| Arm | N | Events | Median (Days) |
|---|---|---|---|
| Standard of care | 38 | 7 | not reached |
| Plasma therapy | 40 | 9 | not reached |
- Standard of care vs Plasma therapy: reconstructed HR 0.74 (95% CI 0.28–1.99)
Landmark survival (reconstructed)
| Time | Standard of care | Plasma therapy |
|---|---|---|
| 24 d | 94.7% | 84.3% |
| 48 d | 80.5% | 78.7% |
| 72 d | 80.5% | 75.3% |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/convalescent-plasma-for-severe-covid-19-in-cancer-patients-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/convalescent-plasma-for-severe-covid-19-in-cancer-patients-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Nat Cancer. 2022 Dec 29;4(1):96–107. doi: 10.1038/s43018-022-00503-w doi:10.1038/s43018-022-00503-w. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/convalescent-plasma-for-severe-covid-19-in-cancer-patients
Report a problem with these data
Related trials
- KHBO1401-MITSUBA: Overall survival; Progression-free survival
- GENERATE: Overall survival (planned interim analysis); Overall survival (updated analysis); Progress
- PANTHEON: Overall survival from start of study; Progression-free survival of second-line therapy (pr
- ADIUVO: Overall survival; Recurrence-free survival
- CONFIRM: Overall survival; Progression-free survival
- JCOG0905: Disease-free survival; Disease-free survival (good responders); Overall survival; Overall
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials